Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.

Oncology reports - 1 Mar 2012

Guo Haisheng, Wan Yunyan, Tian Guangyan, Liu Qinghua, Kang Yanmeng, Li Yuye, Yao Zhouhong, Lin Dianjie

Abstract excerpt

The aim of the present study was to evaluate the therapeutic effects and adverse reactions of Tarceva treatment for malignant pleural effusion (MPE) caused by metastatic lung adenocarcinomas. One hundred and twenty-eight patients who failed first-line chemotherapy drug treatment were divided into a mutation and a non-mutation group according to the presence or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Pleural Effusion, Malignant

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 22134479
DOI: 10.3892/or.2011.1559

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.PMID 22134479Read ↗

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Pleural effusion in lung cancer: more questions than answers.Semantic proximity Read ↗

Survival of lung adenocarcinoma patients with malignant pleural effusion.Semantic proximity Read ↗

Gene mutation characteristics of nonsmall-cell lung carcinoma patients with wild-type epidermal growth factor receptor and sensitivity to Tarceva therapy.Semantic proximity Read ↗

Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.Semantic proximity Read ↗

Prognosis of EGFR-mutant Lung Adenocarcinoma Patients With Malignant Pleural Effusion Receiving First-line EGFR-TKI Therapy Without Pleurodesis: A Single-institute Retrospective Study.Semantic proximity Read ↗

Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab.Semantic proximity Read ↗

[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].Semantic proximity Read ↗

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma.Semantic proximity Read ↗

Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing.Semantic proximity Read ↗

Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation.Semantic proximity Read ↗

The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.